The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. TNKase is delivered as a single ...
The FDA has signed off on Roche's heart attack medicine TNKase to treat stroke. TNKase can be administered faster than the only other stroke medication on the market, Roche's Activase. (iStock / Getty ...
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results